HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma

Although neoadjuvant therapy (Nac) is recommended for high-risk resectable pancreatic cancer (R-PDAC), evidence regarding specific regimes is scarce. This report aimed to investigate the efficacy of S-1 Nac for R-PDAC. In a multicenter phase II trial, we investigated the efficacy of Nac S-1 (an oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Toru, Hayashi, Tsuyoshi, Kimura, Yasutoshi, Kawakami, Hiroshi, Takahashi, Kuniyuki, Ishiwatari, Hirotoshi, Goto, Takuma, Motoya, Masayo, Yamakita, Keisuke, Sakuhara, Yusuke, Ono, Michihiro, Tanaka, Eiichi, Omi, Makoto, Murakawa, Katsuhiko, Iida, Tomoya, Sakurai, Tamaki, Haba, Shin, Abiko, Takehiro, Ito, Yoichi M., Maguchi, Hiroyuki, Hirano, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200853/
https://www.ncbi.nlm.nih.gov/pubmed/35705607
http://dx.doi.org/10.1038/s41598-022-14094-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200853/
https://www.ncbi.nlm.nih.gov/pubmed/35705607
http://dx.doi.org/10.1038/s41598-022-14094-0

Ejemplares similares